TherapeuticsMD posts $1.1M net income from continuing ops in FY2022 vs loss of $79.3M in 2021

TherapeuticsMD, Inc.

2023-Q1 EPS reported -$0.37 vs consensus $0.06 ▼ miss (-704.6%)

License revenue surged to $70.0M from $2.6M, driven by $140M upfront from Mayne Pharma transaction.
Company repaid all $188.3M debt, redeemed Series A preferred stock, and has $38.1M cash on hand.
Discontinued ops generated $80.7M product revenue; net income of $110.9M vs loss in 2021.
Reduced to one full-time employee; transition to virtual royalty model from Mayne Pharma license.
Eligible for up to $30M milestones and 7.5%-8% royalties for 20 years with $3M minimum annual royalties.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TherapeuticsMD, Inc. reported the full year ended December 31, 2022 results: revenue $70.0 million, net income $1.1 million, EPS $0.12 per basic share.

Period: the full year ended December 31, 2022
Revenue: $70.0 million
Net income: $1.1 million
EPS: $0.12 per basic share
Result: reported results

Exact text from the filing

License Revenues from Continuing Operations • License revenues from continuing operations, which are revenues from continuing operations related to license agreements, were $70.0 million for the year ended December 31, 2022, compared to $2.6 million for 2021. The increase in license revenues was a result of the allocation of the initial upfront payment and

View on SEC.gov

16 earnings releases filed in the last 30 days. Browse all earnings releases →

TherapeuticsMD, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-095317

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.